Is this your firm? Get featured or correct your listing →
At a glance
Janus Henderson Investors appears in 5 funding rounds tracked by ValueAddVC since 2026, leading 1. Its most frequent sector in these rounds is Health & Biotech, and its most recent tracked deal was OMass Therapeutics' $310M Series C round (Oct 15, 2026). It co-invests most often with ARCH Venture Partners, Fidelity Investments and Google Ventures (GV).
Strategy
Recent changes
- Oct 15, 2026Oct 15, 2026Invested in OMass Therapeutics (Series C, $310M) ValueSpectrum
- Oct 13, 2026Oct 13, 2026Invested in Souffle Therapeutics (Series B, $135M) FinancialContent
- Sep 16, 2026Sep 16, 2026Invested in Tare (Seed, $13.25M) Fortune Term Sheet
- Sep 9, 2026Sep 9, 2026Invested in Encoded Therapeutics (Series F, $275M) Encoded Therapeutics (Business Wire via BioSpace)
Portfolio
7 totalRecent Investment Activity
5Track record: led 1 and participated in 4 of 5 tracked venture rounds · 5 in the last 12 months · led 1 Series C
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | OMass Therapeutics | Series C | Participated | $310M | — | Bain Capital Life SciencesLeadunverifiedForbionLeadunverifiedGoogle Ventures (GV)unverifiedNorthpond VenturesunverifiedSanofi VenturesunverifiedBritish Business BankunverifiedJanus Henderson InvestorsunverifiedNovo HoldingsSynconaOxford Science EnterprisesSV Health Investors+2 more | ValueSpectrum |
| Oct 13, 2026 | Souffle Therapeutics | Series B | Participated | $135M | — | Fidelity InvestmentsunverifiedARCH Venture PartnersunverifiedBessemer Venture PartnersunverifiedJanus Henderson InvestorsunverifiedLeaps by BayerunverifiedPolaris PartnersunverifiedTemasekunverifiedVida VenturesunverifiedJuvia GroupTCG Crossover ManagementBB BiotechBalyasny Asset Management+5 more | FinancialContent |
| Sep 16, 2026 | Tare | Seed | Participated | $13.25M | — | Blockchain CapitalLeadJanus Henderson InvestorsStrobe Venturesthe Venture DeptNeoclassic Capitalthe Avalanche Foundation+3 more | Fortune Term Sheet |
| Sep 9, 2026 | Encoded Therapeutics | Series F | Participated | $275M | — | Google Ventures (GV)LeadARCH Venture PartnersIllumina VenturesInvusJanus Henderson InvestorsRTW InvestmentsSoftBank Vision FundVenrockBraidwellFarallon Capital ManagementMatrix Capital ManagementNolan Capital | Encoded Therapeutics (Business Wire via BioSpace) |
| Aug 11, 2026 | Epicrispr Biotechnologies | Series C | Led | $90M | — | Janus Henderson InvestorsLeadunverifiedFidelity InvestmentsunverifiedCormorant Asset ManagementunverifiedSanofi VenturesunverifiedOctagon Capital | Epicrispr Biotechnologies |
Sector / Stage Activity
Co-Investors
12Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 15, 2026OMass Therapeutics Raises $310M Series C For Rare DiseaseOxford biotech OMass Therapeutics raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to push its lead GPCR drug candidate through Phase 2.→
- Oct 13, 2026Souffle Therapeutics Raises $135M For RNA TherapiesSouffle Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group on Oct. 13 to push its RNA-delivery platform's first three programs toward the clinic.→
- Aug 12, 2026Form Energy Raises $750M for 100-Hour Grid BatteriesForm Energy raised a $750 million Series G led by T. Rowe Price to expand its iron-air batteries, which store power for up to 100 hours and are being bought by Google, Xcel Energy and Crusoe for AI data center power.→
- Jun 18, 2026Triveni Bio Raises $65M for Antibody Therapeutics in ImmunologyTriveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.→
- Jun 17, 2026Triveni Bio Raises $65M for Antibody-Based Immunology TherapeuticsTriveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.→
Janus Henderson Investors FAQ
What companies has Janus Henderson Investors invested in?
Janus Henderson Investors' portfolio includes OMass Therapeutics, Souffle Therapeutics, Tare, Encoded Therapeutics, Form Energy, Epicrispr Biotechnologies, and 1 more tracked companies.
Who does Janus Henderson Investors co-invest with most?
In the rounds Value Add tracks, Janus Henderson Investors most often invests alongside Fidelity Investments (3 shared deals), ARCH Venture Partners (2 shared deals), Google Ventures (GV) (2 shared deals), Sanofi Ventures (2 shared deals), Aramco Ventures (1 shared deal).
Sources & methodologyshow
- Fortune Term Sheetmajor outlet1 fact
- Encoded Therapeutics (Business Wire via BioSpace)research database1 fact
- FinancialContentresearch database1 fact
- Epicrispr BiotechnologiesValue Add VC data1 fact
- ValueSpectrumValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.